Exagamglogene Autotemcel for Severe Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . Methods We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. Results A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. Conclusions Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationA trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy, S., Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715870 · Cited by 216
Self-citation
Cited by
Items 101–200 of 477
Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies
Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady4877 · Cited by 12
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES
Testa, U., Leone, G., & Cappellini, M. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.068 · Cited by 9
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease
McManus, M. P., Frangoul, H., & Steinberg, M. H. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2429605 · Cited by 10
“In gene therapy treated patients, nearly all erythrocytes were calculated to have at least 10 pg. of HbF/F-cell [34].”
InfluentialSelf-citationLewis, J., Guilcher, G. M. T., & Greenway, S. C. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14247 · Cited by 10
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management
Goldenberg, M. C., Lanzkron, S., & Pecker, L. H. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2423368 · Cited by 7
Grilley, B., Hume, A., & Galipeau, J. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.01.008 · Cited by 6
Steinberg, M. H., Kutlar, A., & Sebastiani, P. (2025) · American Journal of Hematology · doi:10.1002/ajh.27729 · Cited by 6
Self-citationBangolo, A., Amoozgar, B., Zhang, L., Gill, S. K., Milolo, D. L., Kankonde, J. N., Batakamuna, C. M., Tassan, R., Cho, C., Bukasa-Kakamba, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13082022 · Cited by 9
“Furthermore, manufacturing complexity, cost, and requirement for high-dose chemotherapy pose barriers, particularly in LMICs [69].”
A clinical roadmap for base and prime editing
Flugel, C., Cadiñanos-Garai, A., & Abou‐El‐Enein, M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00360-z · Cited by 6
Ramadas, N., & Sparkenbaugh, E. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103193 · Cited by 8
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
“%) of the patients were free of hospitalizations for a vaso-occlusive crisis for at least twelve consecutive months [99].”
Clinical data comparison for FDA-approved gene therapies in sickle cell disease
Leonard, A. K., & Kanter, J. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10806 · Cited by 8
“Updated data can be found in subsequent publications or presentations [10, 12].”
Tanhehco, Y. C., Thibodeaux, S. R., Shi, P. A., Chou, S. T., Kelly, S., Monis, G. F., Newton, C., West, K. A., Zheng, Y., Fernandez, C. M., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016054 · Cited by 8
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 8
Sharma, A., Kassim, A. A., Thompson, A. A., Williams, D. A., Liu, H. D., Boelens, J. J., LaBelle, J. L., Tisdale, J. F., de la Fuente, J., Kanter, J., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.03.019 · Cited by 9
Self-citationChen, V. L., & Brady, G. F. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000618 · Cited by 11
A New Oxygen Carrier for Therapeutic Applications
Barrou, B., Leize‐Zal, E., & Zal, F. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3847 · Cited by 5
Sickle Cell Disease in 2024: One Step Forward and Two Steps Back
Wilson, S., & Little, J. A. (2025) · The Hematologist · doi:10.1182/hem.v22.1.2025212 · Cited by 5
Hmaidan, S., Heertum, K. V., Bhatia, S., Domm, J., McManus, M. P., Carroll, C., Stults, A., Bruce, K., Evans, M. D., & Frangoul, H. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.08.004 · Cited by 5
Self-citationLandscape of ex vivo gene therapies: Technological trends and future prospects
Almeida-Oliveira, A., Bonamino, M., Simões, M., Martins, V. H. V., Freire, D. P. B., Danowski, A., Catão, T. P., Varela, J. D. N. E. S., Mazzi, M. T., Gottgtroy, C., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101580 · Cited by 6
Lisbon, E. A., Brown, C., Redfern, A., Duchin, K., Barth, A., Roberts, E. S., Gaputan, P., Dufu, K., Lo, A., Pochron, M. P., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70028 · Cited by 6
“3 Recently, interest in therapeutic options for SCD has been renewed by gene therapies; 4,5 however, they impose potential risks and can be prohibitively costly, underscoring the need for other accessible treatment options.”
Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT
Marco, E., Sousa, P., Janoudi, T., Dreuzy, E. D., Heath, J. M., Viswanathan, R., Zuris, J. A., Gotta, G. M., Giannoukos, G., Hansen, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.031 · Cited by 9
Self-citationRNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
Chakraborty, C., Bhattacharya, M., Das, A., Agoramoorthy, G., & Lee, S.-S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102859 · Cited by 12
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
Ambardekar, A. V., Bhatt, A., Hoekstra, M., Kelly, M., Musunuru, K., & Natarajan, P. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5092 · Cited by 13
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, S., Hovnanian, A., Xiong, G., Murrell, D. F., Mueller, S. M., Ezzedine, K., Aghazadeh, N., Aldhaheri, A. S., Asayag, N., Baselga, E., et al. (2026) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70483 · Cited by 5
Verheul, T. C. J., Gillemans, N., Putzker, K., Majied, R., Li, T., Vasiliou, M., Eussen, B., de Klein, A., van IJcken, W. F. J., van den Akker, E., et al. (2024) · HemaSphere · doi:10.1002/hem3.139 · Cited by 6
Liu, B., Klatt, D., Zhou, Y., Manis, J. P., Sauvageau, G., Pellin, D., Brendel, C., & Williams, D. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013932 · Cited by 8
Kassim, S. H., Urnov, F. D., Musunuru, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02744-3 · Cited by 5
Sharma, A., & John, T. D. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015413 · Cited by 5
Self-citationEpigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
“…in sustained normal Hb levels 12.5 ± 1.8 g /dl for SCD and 13.1 ± 1.4 g /dl for beta-thalassemia patients After the gene therapy, the 91% of the thalassemic patients were transfusion independent and the 97% of the SCD had reduced vaso-occlusive crisis for a period of 12 months or more [217–219].”
InfluentialThe racial politics of visibility and equity in genome-editing therapies for sickle cell disease
Molina, S. J., & Creary, M. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118452 · Cited by 4
Precision T cell correction platform for inborn errors of immunity
Mamia, K., Kolbeinsdóttir, S., Labun, K., Li, Z., Komisarczuk, A. Z., Keskitalo, S., Reint, G., Haugen, F. L., Lindestad, B. O., Jensen, S. S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.018 · Cited by 5
Hematopoietic stem cell therapy with gene modification to treat sickle cell disease
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf042 · Cited by 8
CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential
Wei, Y., Sun, J. Y., & Zhu, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.031 · Cited by 7
Ex Vivo Gene and Cell Therapy in Hematopoietic Stem Cells
Petrova, I. O., & Smirnikhina, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311466 · Cited by 6
“CRISPR/Cas ribonucleoprotein carrying sgRNA for erythroid-specific enhancer region of the BCL11A gene is delivered by electroporation into autologous CD34+ HSPCs [57].”
Targeting LncRNAs with CRISPR/Cas9 for Kidney Therapeutics: A Review
Puri, B., & Gaikwad, A. B. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149932 · Cited by 4
Cunningham, R. A., Gottimukkala, K. S. V., Lane, D. D., Poljakov, K., Lipson, P., Enstrom, M., Rizzi, A. M., Chapuis, A. G., & Adair, J. E. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500242 · Cited by 6
“The first authorized CRISPR therapy (exagamglogene autotemcel) utilizes ex vivo manipulation of patient hematopoietic stem and progenitor cells (HSPCs) to functionally cure sickle cell disease (SCD) [4], a serious condition which affects more than 8 million people worldwide [5].”
Precision genome editing with DNA base editors
Mawson, S. J., Dunne-Dombrink, K., Pollak, B. R., & Komor, A. C. (2026) · Nature Reviews Methods Primers · doi:10.1038/s43586-026-00478-3 · Cited by 9
Canarutto, D., Fiumara, M., Venkatesan, V., Gaddoni, C., Shiroshita, K., Varesi, A., Albano, L., Pelosi, G., Silva, A., Firrito, C., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03142-z · Cited by 6
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 10
Handgretinger, R., & Mezger, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2399134 · Cited by 9
Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges
Yang, P., Khoshandam, M., Bhia, I., Raji, S., Soltaninejad, H., Hosseinkhani, S., Sani, M., Hamidieh, A. A., & Sheykhhasan, M. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101068 · Cited by 10
“…the HBG1 and HBG2 gene promoters to induce HbF production, resulted in a decrease in SCD manifestations during the follow-up period (6–18 months) as well [ 70 ]. β -thalassemia shares a similar pathology and physiology as SCD (mutation in β subunit gene); therefore, it can be approached similarly.”
Abdelazim, O., Sharafeldin, A.-B. K., Kawari, M., Hasan, Z. A. I. Y., & Toorani, Z. A. (2025) · Stem Cells and Development · doi:10.1177/15473287251362882 · Cited by 6
Recent advances and clinical prospects of non-viral brain-targeted gene delivery systems
Wang, S., Xu, L.-L., Ma, F., Xu, M., Chen, G., Wang, D., Wu, X., Wang, P., Yu, J., & Shi, L. (2025) · Applied Physics Reviews · doi:10.1063/5.0255745 · Cited by 4
Gene Therapy for Inherited Arrhythmia Syndromes
Leong, C. J., Sharma, S., Seth, J., Dave, A., Ghafoor, A. A. A., & Laksman, Z. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030011 · Cited by 5
“Exagamglogene autotemcel is a cell-based therapy involving infusion with autologous hematopoietic stem cell progenitors that have been genetically edited to express fetal hemoglobin using CRISPR-Cas9 [19].”
MethodGene Therapies for Sickle Cell Disease
Weaver, S. B., Singh, D., & Wilson, K. M. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241268742 · Cited by 6
Fostering a healthier generation of children with sickle cell disease through advancements in care
Franco, E., Nimura, C. A., & McGann, P. T. (2024) · Pediatric Research · doi:10.1038/s41390-024-03566-w · Cited by 6
The genetic and molecular basis of a connexin-linked skin disease
Lucaciu, S. A., & Laird, D. W. (2024) · Biochemical Journal · doi:10.1042/bcj20240374 · Cited by 8
Michicich, M., Traylor, Z., McCoy, C., Valerio, D. M., Wilson, A., Schneider, M., Davis, S., Barabas, A. J., Mann, R. J., LePage, D. F., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.10.008 · Cited by 6
The evolving landscape of NF gene therapy: Hurdles and opportunities
O’Donohue, A. K., Ginn, S. L., Burgio, G., Berman, Y. D., Dabscheck, G., & Schindeler, A. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102475 · Cited by 8
Felder, A.-K., Tjalsma, S. J. D., Verhagen, H. J. M. P., Majied, R., Verstegen, M. J. A. M., Verheul, T. C. J., van Haren, J., Mohnani, R., Gremmen, R., Krijger, P. H. L., et al. (2025) · Blood · doi:10.1182/blood.2024028128 · Cited by 8
Shahid, A. M., Vainchenker, W., & Constantinescu, S. N. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70700 · Cited by 7
A new breakthrough in genome editing: the story of Casgevy
Olalla-Sastre, B., & Rı́o, P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.003 · Cited by 4
In cellulo DNA assembly for targeted genomic integration and rearrangement in human cellsPreprint
Levesque, S., Kawashima, N., Hwang, G., Becerra, B., Schoonenberg, V. A. C., Mannherz, W. P., Homfeldt, L., Pinello, L., Agarwal, S., & Bauer, D. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659926 · Cited by 4
Aloofy, T. A., Aleem, A., AlGahtani, F. H., Alshehri, A. M., & Alsultan, A. S. (2025) · Hemoglobin · doi:10.1080/03630269.2025.2462174 · Cited by 5
Wilks, A., Steinberg, M. H., & Frangoul, H. (2025) · Blood · doi:10.1182/blood.2025029964 · Cited by 3
Self-citationChakravorty, S., & Greenough, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2551353 · Cited by 4
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
Yen, A., Boitano, T., Zappala, Z., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2503294 · Cited by 3
Gene therapy for inborn errors of immunity: past progress, current status and future directions
Torrance, R. W., Orf, K., & Fox, T. A. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.42 · Cited by 8
Krishnamurti, L., Olafimihan, A. G., & Hsu, L. L.-Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017015 · Cited by 4
Hudock, M. R., Daly, G. W., Rivas, D., Patel, A., Chen, J., Morsink, M. A. J., Goduco, Y., Pinezich, M. R., Mir, M., Hassel, J. V., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01527 · Cited by 4
Arcioni, F., Bonetti, M., Sau, A., Zecca, M., Alzahrani, M., Alahmari, B., Alsadi, H. M., Almozaini, A., Ahmed, M., Essa, M., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70167 · Cited by 6
“In the CLIMB SCD-121with plerixafor alone, the median number of mobilization cycles was two (range, 1–6) with 32% of patients undergoing three or more cycles and with three more patients discontinuing due to inadequate cell collections [4].”
InfluentialTraxler, E. A., Hotan, Q., Shao, Y., Komar, C. A., Chen, Q., Saari, M. S., Thrasher, A. J., Yang, S., Qin, K., Wang, M. Y., et al. (2026) · Blood · doi:10.1182/blood.2025030137 · Cited by 3
Miniaturized CRISPR: Ultra Compact Systems for In Vivo Delivery and Portable Diagnostics
Saxena, S., Saxena, S., & Gupta, D. (2026) · Annals of Biomedical Engineering · doi:10.1007/s10439-026-04046-4 · Cited by 4
Lei, L., Kaufmann, M. M., Lao, J., Thoulass, G., Ammann, S., Xiao, H., Rhiel, M., Dettmer‐Monaco, V., Grünewald, J., Andrieux, G., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.014 · Cited by 6
Esrick, E. B., Lehmann, L., Federico, A., Vincon, H., Liu, B., Daley, H., Dansereau, C., Oliveira, S. D., Everett, J. K., Kao, P., et al. (2026) · Blood · doi:10.1182/blood.2026033871 · Cited by 3
Chalumeau, A., Antoniou, P., Dames, M. B., Martinucci, P., Retana, E., Gupta, P., Firth, M. A., Reddivari, M., Chandran, A. S., Yen, J. S., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102974 · Cited by 4
Applications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 4
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud, Y., Leonard, A. K., & Rai, P. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2379260 · Cited by 4
John, T. D., Walters, M. C., Rangarajan, H. G., Rahim, M. Q., McKinney, C. M., Bollard, C. M., Abusin, G. A., Eapen, M., Kassim, A. A., & DeBaun, M. R. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014078 · Cited by 4
Self-citationAlloimmunization as a barrier to gene therapy in sickle cell disease
Abrams, H. R., Saifee, N. H., Miller, W. S., Cortez, A., Hasan, R. A., Panch, S. R., & Fertrin, K. Y. (2025) · Transfusion · doi:10.1111/trf.18266 · Cited by 3
Gene therapy in neuronopathic lysosomal storage disorders
Donald, A., Horgan, C., López, M. J. D. C., Jones, S., & Wynn, R. F. (2025) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2025.05.010 · Cited by 7
Gibson, N. M., Elgarten, C. W., Oved, J. H., Wray, L., Freedman, J. L., Khandros, E., Worster, E., Nicholas, P., Kadauke, S., Wang, Y., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.06.029 · Cited by 4
Self-citationBlood-based protein biomarkers of sickle cell disease pain: a systematic review and meta-analysis
Mirbeyk, M., Misra, S., Koneru, G., Funaro, M. C., Rangaraju, S., & Bakshi, N. (2025) · Pain · doi:10.1097/j.pain.0000000000003773 · Cited by 4
Extending Gene Medicines to All in Need
McCune, J. M., & Kiem, H. (2024) · New England Journal of Medicine · doi:10.1056/nejme2403104 · Cited by 4
Advances in pharmacotherapy for sickle cell disease: what is the current state of play?
Alan, S., & Kanter, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2377711 · Cited by 3
Challenges and Outlooks in Precision Medicine: Expectations Versus Reality
Yan, R. E., & Greenfield, J. P. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.06.142 · Cited by 4
Maurer, K., & Jacobson, C. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2460043 · Cited by 5
The Past, the Present, and the Future of Genomic Therapies in Cardiovascular Disease
McNally, E. M., Puckelwartz, M. J., & Nóbrega, M. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035987 · Cited by 4
Felder, A.-K., Tjalsma, S. J. D., Verhagen, H. J. M. P., Majied, R., Verstegen, M. J. A. M., Verheul, T. C. J., Mohnani, R., Gremmen, R., Krijger, P. H. L., Philipsen, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632719 · Cited by 3
Senolytics restore hematopoietic stem cell function in sickle cell diseasePreprint
Barve, A., Cornwell, A. B., Sriram, P., Kopyov, O. V., Dabas, P., Kooienga, E., Kelley, Z., Johnson, J. D., Myers, J., Obeng, E. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.08.636742 · Cited by 3
Self-citationThe future of ex vivo hematopoietic stem cell gene editing: what’s next
Cavazza, A., & Santilli, G. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2480003 · Cited by 5
“…regions or genes via NHEJ/ MMEJ repair, as exemplified by the recent approval of Casgevy ® for the treatment of β-hemoglobinopathies, where induced insertions and deletions (indels) in the erythroid enhancer of the BCL11a gene activate γ-globin, compensating for the loss of functional β-globin [3].”
Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapyPreprint
Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651174 · Cited by 3
Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A
Solano, L. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000142 · Cited by 2
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2
Direct and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1
Coyne, S. M., Hwang, G.-H., Wu, T., Hossain, M. A., Vinjamur, D. S., Starrs, M. M., Zeng, J., Andresen, F., Gutierrez, A. M., Shimamura, A., et al. (2026) · Blood · doi:10.1182/blood.2025031840 · Cited by 5
Gene Therapy for Wet Age-Related Macular Degeneration
Barthelemy, N., Sridhar, J. S., & Sengillo, J. D. (2025) · Bioengineering · doi:10.3390/bioengineering12101072 · Cited by 6
“In addition, CRISPR-based therapies have been approved for sustained remission in both beta-thalassemia and sickle cell disease [59,60].”
Huang, H., & Ouyang, J. (2025) · Oncology Letters · doi:10.3892/ol.2025.15358 · Cited by 3
Aprile, A., Lidonnici, M. R., & Ferrari, G. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102419 · Cited by 7
“27,28 On the basis of these promising results, FDA approved exa-cel (Casgevy) for the treatment of patients 12-year and older with SCD in 2023 and with TDT in January 2024.”
Advances in Gene Therapy for Inherited Haemoglobinopathies
Gaspar, A. B., & Gaspar, H. B. (2025) · Hematology Reports · doi:10.3390/hematolrep18010004 · Cited by 4
“…[11] Clinical trial Gene Silencing Lentiviral knockdown of BCL11A [12] Clinical trial Gene Editing CRISPR/Cas9 editing of BCL11A erythroid enhancer [13] Approved gene therapy CRISPR/Cas9 editing of HBG1/2 [14] Clinical trial—discontinued ZFN editing of GATAA [15] Clinical trial Base Editing Base…”
InfluentialGene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism
Benedetti, D. J., Marron, J. M., & Kodish, E. D. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01844 · Cited by 2
CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications
Rahmanian, M., Khoshandam, M., Mousazadeh, M., Yang, P., Soltaninejad, H., Dehkordi, P. K., Sadeghizadeh, M., Goudarzi, M. T. H., Azimi, A. H., & Sheykhhasan, M. (2026) · Human Gene Therapy · doi:10.1177/10430342251409714 · Cited by 8
Overview of gene editing strategies against HBV
Janetzki, Z. T., McCoullough, L. C., Revill, P. A., & Littlejohn, M. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106355 · Cited by 4
Rules, risks, and reality: rethinking gene therapy eligibility
Karsenty, C. L., & Ngwube, A. I. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018621 · Cited by 2
Testa, U., Castelli, G., & Pelosi, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041379 · Cited by 4
“…autologous CD34 + cells in 44 transfusion-dependent SCD patients; the majority (38/44) of treated patients were free of hospitalizations for severe vaso-occlusive events; all patients became transfusion-independent, and their Hb content increased from <9 g/dL to 12.5 g/dL, with 44.5% of HbF [175].”
InfluentialCalcium Shock Enables Efficient and Programmable Particle Delivery for Genome Editing Applications
Vo, N., de Oñate, L., Frank, M., Hu, X., Blackburn, S. M., Foss, D. V., Villegas, J., Asija, K., Hockemeyer, D. F., Fu, H., et al. (2026) · Advanced Science · doi:10.1002/advs.202510441 · Cited by 2
Transfusion utilization during gene therapy for sickle cell disease: A single institution experience
Fasano, R. M., Cappello, E. M., Jacob, R. P., Zerra, P. E., Haight, A. E., Parikh, S. H., Stenger, E. O., & Yee, M. E. M. (2026) · Transfusion · doi:10.1111/trf.70189 · Cited by 2
More Options for Gene Editing in Hemoglobinopathies
Locatelli, F. (2026) · New England Journal of Medicine · doi:10.1056/nejme2602194 · Cited by 2
Self-citation
Metadata
- Authors
- Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., Eckrich, M. J., Imren, S., Bower, L., Simard, C., Zhou, W., Xuan, F., Morrow, P. K., Hobbs, W. E., & Grupp, S. A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; IRCCS, Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.); the Department of Pediatrics, Columbia University Irving Medical Center, New York–Presbyterian–Morgan Stanley Children’s Hospital (M.B.), and the Department of Medicine, Division of Hematology–Oncology, Columbia University (M. Mapara) — both in New York; Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX (L.M., M.J.E.); the Hospital for Sick Children and the University of Toronto, Toronto (D.W.); Ann and Robert H. Lurie Children’s Hospital of Chicago (R.I.L.) and the University of Illinois at Chicago (D.R.) — both in Chicago; Royal London Hospital, Barts Health NHS Trust, London (P.T.); Stanford University, Palo Alto (A.J....
- ORCID
- Frangoul, Haydar
- Locatelli, Franco
- Sharma, Akshay
- Bhatia, Monica
- Mapara, Markus
- Wall, Donna
- Liem, Robert I.
- Telfer, Paul
- Shah, Ami J.
- Cavazzana, Marina
- Corbacioglu, Selim
- Rondelli, Damiano
- Meisel, Roland
- Dedeken, Laurence
- Lobitz, Stephan
- Steinberg, Martin H.
- Walters, Mark C.
- Eckrich, Michael J.
- Imren, Suzan
- Zhou, Weiyu
- Xuan, Fengjuan
- Morrow, Phuong Khanh
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1649-1662
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068280
- Cited by
- 493
- References
- 29
- Citations by year
- 2026: 217 · 2025: 201 · 2024: 74
- FWCI
- 137.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vertex Pharmaceuticals
- CRISPR Therapeutics
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, sickle cell disease, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin reactivation, hematopoietic stem and progenitor cells, vaso-occlusive crisis, myeloablative conditioning, busulfan, autologous cell transplantation, cell therapy safety, pediatric patients
- MeSH terms
- Gene Editing, Adolescent, Adult, Anemia, Sickle Cell, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.